Revenue declined 4.8% to ₹904.2 crore versus ₹949.5 crore a year earlier. EBITDA fell 11.2% to ₹201.1 crore from ₹226.4 crore in the corresponding quarter of the previous year. EBITDA margin contracted to 22.2% from 23.9% year-on-year.
The company’s India business grew 2% year-on-year during the quarter to ₹526 crore. For FY26, the India business rose 9% to ₹2,461 crore, while the branded generics business grew 11%.
Also Read: JB Chemicals appoints Aman Mehta as MD; four new directors join board
According to IQVIA MAT March 2026 data, the India business recorded 11% growth against the Indian pharmaceutical market growth of 10%. The chronic portfolio grew 19%, compared with industry growth of 14%. Secondary market growth also stood at 11%, indicating underlying growth momentum for both the quarter and full year.
The company said Q4 performance included one-off impacts from distribution network optimisation initiatives undertaken during the integration process, discontinuation of low-margin trade generics products, alignment of trade and sales closing practices with the parent entity, and changes in cut-off policies that resulted in a timing impact on quarterly revenue.
International formulations business declined 9% year-on-year to ₹259 crore in Q4FY26. For FY26, international formulations revenue increased 2% to ₹1,154 crore.
Also Read: Torrent Pharma shares gain 4% after steady Q3; Street positive on JB merger benefits
The company said international business performance was impacted by inventory rationalisation, changes in credit practices following the change of control and alignment with parent company practices, as well as shipment delays due to container constraints in overseas markets. Some shipments to the Middle East remain on hold, while others are expected to be shipped during Q1.
CDMO revenue declined 22% year-on-year in Q4 due to a high base in the corresponding quarter of the previous year. For FY26, CDMO revenue remained flat at ₹445 crore. The company said CDMO business growth was impacted by the higher base of previous years and lower inventory held by customers.
Shares of JB Chemicals and Pharmaceuticals Ltd ended at ₹2,215.00, up by ₹63.10, or 2.93%, on the BSE.
Also Read: JB Chemicals and Pharma Q3 Results: Profit up 22% as domestic biz outpaces market
(Edited by : Jomy Jos Pullokaran)
First Published: May 11, 2026 9:08 PM IST
